文献速递头颈与中枢神经肿瘤

18F-FDG PET/CT监测在头颈癌患者复发检测中的应用

18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer.
PubMed 文献 · Eur J Cancer · 2016-12-24

这项前瞻性研究纳入278例接受根治性手术或根治性放化疗的头颈鳞状细胞癌患者,治疗后定期以18F-FDG PET/CT、头颈CT/MRI和胸部CT随访。中位随访44个月,73例(26.3%)出现复发或持续病变;PET/CT诊断复发的AUC为0.975,高于CT/MRI的0.789(P < 0.001),且PET/CT阳性为癌症特异性和总生存较差的独立预测因素(P < 0.01)。

要点

  • 治疗后18F-FDG PET/CT监测有助于检出复发并预测头颈鳞癌治疗后的生存。
  • PET/CT诊断复发的AUC为0.975,高于CT/MRI的0.789(P < 0.001)。
  • PET/CT检出66例复发中的65例(98.5%),这些复发未被体格检查和内镜提示。

核心结论

  • 治疗后18F-FDG PET/CT监测有助于恰当检出复发并预测头颈鳞状细胞癌治疗后的生存。

研究设计与样本

  • 前瞻性研究纳入278例既往未经治疗的头颈鳞状细胞癌患者,其中根治性手术143例(51.4%)、根治性放疗/放化疗135例(48.6%)。
  • 治疗后定期以18F-FDG PET/CT、头颈CT/磁共振成像(MRI)和胸部CT随访评估,影像判读与复发组织学结果比较。
  • 采用受试者工作特征曲线分析、McNemar检验和广义估计方程逻辑回归比较诊断准确性,Cox比例风险模型评估预后价值。

主要发现

  • 中位随访44个月(范围24-62个月)期间,73例(26.3%)出现复发或持续病变。
  • 18F-FDG PET/CT与CT/MRI诊断复发的曲线下面积分别为0.975(0.964-0.992)和0.789(0.713-0.874)(P < 0.001)。
  • 18F-FDG PET/CT检出66例复发中的65例(98.5%),这些复发未被体格检查和内镜提示。
  • 18F-FDG PET/CT扫描阳性发现是癌症特异性生存和总生存较差的独立预测因素(P < 0.01)。

临床怎么用

  • 原文结论认为,治疗后18F-FDG PET/CT监测有助于恰当检出复发并预测头颈鳞状细胞癌治疗后的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posttreatment detection of recurrence may lead to salvage treatment and prognostic prediction in patients with head and neck squamous cell carcinoma (HNSCC). We evaluated the diagnostic and prognostic values of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) after definitive treatment of HNSCC. METHODS: This prospective study included 278 consecutive patients who underwent curative surgery (n = 143, 51.4%) or definitive radiotherapy/chemoradiotherapy (n = 135, 48.6%) for previously untreated HNSCC. The patients were regularly followed up and evaluated by 18F-FDG PET/CT, head and neck CT/magnetic resonance imaging (MRI), and chest CT at regular intervals after treatment. The imaging interpretations were compared with the histological results for recurrence. Receiver operating characteristics curves analysis, McNemar's test and logistic regression using generalised estimating equations were used to compare the diagnostic accuracy of 18F-FDG PET/CT and standard imaging of CT/MRI or chest CT, and a Cox proportional hazards model was used to assess the prognostic value of PET/CT. RESULTS: During a median follow-up of 44 months (range, 24-62 months), 73 patients (26.3%) had recurrence or persistent diseases. The area under curves for 18F-FDG PET/CT and CT/MRI were 0.975 (0.964-0.992) and 0.789 (0.713-0.874), respectively (P < 0.001). 18F-FDG PET/CT detected 65 of 66 recurrences (98.5%) not suggested by physical examination and endoscopy. Positive findings on 18F-FDG PET/CT scans were independent predictors of poorer cancer-specific and overall survival outcomes (P < 0.01). CONCLUSIONS: Posttreatment 18F-FDG PET/CT surveillance helps to properly detect recurrence and to predict the survival following treatment of HNSCC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kim SA, Roh JL, Kim JS, et al. 18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer. Eur J Cancer. 2016. PMID: 28027517. doi:10.1016/j.ejca.2016.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。